Taiho Oncology

What Taiho Oncology does

Taiho Oncology, Inc. is a US-based specialty pharmaceutical company, headquartered in Princeton, New Jersey, and operating as a subsidiary of Taiho Pharmaceutical Co., Ltd., which itself sits within the publicly traded Otsuka Holdings group. The company develops and commercializes orally administered anti-cancer agents across two therapeutic pillars: hematologic malignancies and solid tumors. Its three FDA-approved products are INQOVI (decitabine and cedazuridine), the first oral hypomethylating regimen for MDS, CMML, and now, with venetoclax, AML; LONSURF (trifluridine/tipiracil), an oral nucleoside analog approved for metastatic colorectal cancer and gastric/gastroesophageal junction adenocarcinoma, including in combination with bevacizumab; and LYTGOBI (futibatinib), an irreversible covalent FGFR inhibitor for cholangiocarcinoma harboring FGFR2 fusions. The pipeline adds zipalertinib (an EGFR exon 20 insertion TKI co-developed with Cullinan, PDUFA Feb 2027), ARC-02 (a CD79b-targeted ADC using the Araris AraLinQ/Arastatin platform), and risovalisib (a Japan-approved PIK3CA inhibitor licensed from Haihe Biopharma).

Underlying technology centers on three differentiated platforms: (1) the cedazuridine-enabled oral decitabine chemistry that achieves systemic exposure comparable to IV decitabine, (2) covalent FGFR2 binding chemistry for futibatinib with an irreversible mechanism relative to reversible competitors, and (3) the AraLinQ site-specific antibody conjugation platform acquired with Araris Biotech for next-generation ADCs.

Taiho Oncology generates revenue through prescription product sales distributed via specialty pharmacy channels and authorized distributors (McKesson Specialty Health, ASD Healthcare, Oncology Supply, Cardinal Specialty Health) serving 340B and inpatient hospital channels, supplemented by co-commercialization profit-share arrangements (Cullinan on zipalertinib in the US, Servier for LONSURF in ex-US territories), inbound and outbound licensing royalties (e.g., risovalisib in-license from Haihe for Japan), and a Taiho Ventures arm that places strategic biotech investments. Customers are oncologists and hematologists treating defined patient populations in MDS/CMML/AML, mCRC, gastric cancer, cholangiocarcinoma, and EGFR exon 20 NSCLC, supported by medical information services, a US sales force, and patient assistance/co-pay programs. The company operates across the US, Canada, Switzerland (European HQ), Japan, China, Singapore, the UK, and the Netherlands.

Name

Taiho Oncology

Legal name

Taiho Oncology, Inc.

Website

https://taihooncology.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

251–500 employees

Short description

Taiho Oncology is a US-based specialty pharmaceutical subsidiary of Taiho Pharmaceutical (Otsuka Holdings) that develops and commercializes orally administered anti-cancer agents — INQOVI, LONSURF, and LYTGOBI — for hematologic malignancies and solid tumors, serving oncologists, hematologists, and patients across the US, Europe, Canada, and Asia.

Ownership category

akta.pro rank

Product category

Oncology Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

akta.pro secondary industries

Oncology Specialty Pharmaceuticals (HLAIACAA), Rare Oncology & Hematologic Malignancy Therapies (HLAIAIAC), Medical Oncology (HLAKAFAB), Digestive Oncology (GI Cancer Care) (HLAKAEAF), Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI)

Keywords

• Oral oncology therapeutics
• Anti-cancer pharmaceuticals
• Precision oncology drugs
• Hematologic malignancy treatments
• Antibody-drug conjugates

Headquarters

HQ city

Princeton

HQ country

United States

HQ region

North America

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

1. Pharmaceutical Product Sales: Taiho Oncology generates revenue through the sale of prescription oncology medications including INQOVI, LONSURF, and LYTGOBI. Products are distributed through specialty pharmacy networks and authorized distributors for 340B and hospital use.
2. Co-commercialization Revenue: Revenue sharing arrangements with partners such as Cullinan Therapeutics for zipalertinib in the US market and Servier for LONSURF in certain territories.
3. Licensing and Royalty Income: Taiho Pharmaceutical grants licenses to partners such as Haihe Biopharma for risovalisib in Japan, generating licensing and milestone payments.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Taiho Oncology develops, manufactures, and commercializes prescription orally administered anti-cancer pharmaceutical products for hematologic malignancies and solid tumors. Its marketed portfolio includes INQOVI (decitabine/cedazuridine) for MDS, CMML, and AML; LONSURF (trifluridine/tipiracil) for metastatic colorectal and gastric cancers; and LYTGOBI (futibatinib) for cholangiocarcinoma with FGFR2 fusions. The pipeline adds zipalertinib (EGFR exon 20 NSCLC), ARC-02 (CD79b ADC for lymphoma), and risovalisib (PIK3CA ovarian cancer). Products are sold through specialty distributors, specialty pharmacies, and co-commercialization partners.

Product overview

Taiho Oncology is a pharmaceutical company focused on developing and commercializing orally administered anti-cancer agents for hematologic malignancies and solid tumors. The company's product portfolio includes three approved marketed products: INQOVI (decitabine and cedazuridine) for MDS, CMML, and AML; LONSURF (trifluridine/tipiracil) for metastatic colorectal and gastric cancers; and LYTGOBI (futibatinib) for cholangiocarcinoma. The pipeline includes zipalertinib (EGFR inhibitor for NSCLC) awaiting FDA approval and ARC-02 (ADC for lymphoma) in Phase 1 development. Taiho operates as a subsidiary of Taiho Pharmaceutical Co., Ltd., part of Otsuka Holdings Co., Ltd.

Differentiator

Problem solved

Functional benefit

Products and services

• INQOVI (decitabine and cedazuridine) Orally administered fixed-dose combination of the DNA hypomethylating agent decitabine with cedazuridine (a cytidine deaminase inhibitor) that enables oral delivery achieving systemic exposure comparable to IV decitabine. Approved for MDS, CMML, and in combination with venetoclax for AML. Prescribed by oncologists and hematologists.
• LONSURF (trifluridine and tipiracil) Oral combination anticancer drug of trifluridine (FTD), an antineoplastic nucleoside analog incorporated directly into DNA, and tipiracil hydrochloride, which inhibits thymidine phosphorylase to maintain FTD blood concentration. Approved for metastatic colorectal cancer, gastric/gastroesophageal junction adenocarcinoma, and in combination with bevacizumab for mCRC. Prescribed by oncologists.
• LYTGOBI (futibatinib) Oral, potent, selective, and irreversible (covalent) inhibitor of fibroblast growth factor receptors 1, 2, 3, and 4. Indicated for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or rearrangements. Prescribed by oncologists for genomically defined patient populations.
• Zipalertinib (CLN-081/TAS6417) Oral EGFR tyrosine kinase inhibitor that selectively targets cells expressing EGFR exon 20 insertion mutations while sparing cells expressing wild-type EGFR. Being developed in collaboration with Cullinan Therapeutics for NSCLC with EGFR exon 20 insertion mutations. Targeted for FDA approval in 2027.
• ARC-02 CD79b-targeted antibody-drug conjugate delivering monomethyl auristatin E (MMAE) payload, built using AraLinQ site-specific conjugation at the Q295 Fc attachment site and the Arastatin linker-payload platform with hydrophilic peptide linker. In Phase 1 clinical development for non-Hodgkin lymphoma, representing Taiho's expansion into ADC-based oncology therapies.
• Risovalisib (Haizexin) PIK3CA inhibitor approved in Japan for PIK3CA-mutant advanced or recurrent ovarian clear cell carcinoma, used together with the AmoyDx PIK3CA Mutation Detection Kit as a companion diagnostic to identify eligible patients.

Quantifiable outcome

• INQOVI+venetoclax achieved 41.6% complete response rate with median time to CR of 2 months in newly diagnosed AML patients ineligible for intensive chemotherapy
• +4 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Eight partnerships are on record, tiered regional, core and minor.

• Haihe BiopharmaregionalOEM/ Whitelabel/ Licensing Partner · 1 October 2025Taiho licensed risovalisib from Haihe Biopharma in October 2025, receiving exclusive rights to develop, manufacture, and commercialize in Japan. Japan's Ministry of Health approved risovalisib (brand name Haizexin) for PIK3CA-mutant advanced or recurrent ovarian clear cell carcinoma along with AmoyDx companion diagnostic.
• Araris Biotech AGcoreStrategic or Co-development Partner · 1 March 2025Taiho Pharmaceutical acquired Araris Biotech in March 2025 to strengthen biologics and ADC research capabilities. ARC-02 (CD79b-targeted ADC) represents the first clinical candidate using Araris' proprietary AraLinQ ADC technology and Arastatin linker-payload platform. Phase 1 trial initiated for non-Hodgkin lymphoma treatment, marking Taiho's expansion into ADC-based oncology therapies.
• Cullinan TherapeuticscoreStrategic or Co-development Partner · 12 May 2022Strategic collaboration for joint development and commercialization of zipalertinib (CLN-081/TAS6417). Taiho obtained exclusive global rights outside US; US co-development and co-commercialization with equal profit sharing. Cullinan received $275M upfront and up to $130M in regulatory milestones. NDA accepted by FDA with PDUFA date February 27, 2027.
• National Cancer Institute (NCI)minorStrategic or Co-development Partner · 28 October 2020Cooperative Research and Development Agreement (CRADA) for oral decitabine/cedazuridine tablets. NCI's Cancer Therapy Evaluation Program accepting proposals for evaluation in hematological malignancies and solid tumors, including combination with other investigational agents.
• MD Anderson Cancer CenterminorStrategic or Co-development Partner · 8 September 2020Strategic collaboration with Astex Pharmaceuticals and MD Anderson to accelerate clinical evaluation of therapies for leukemia including MDS, CMML, and AML. Combines MD Anderson's clinical trials infrastructure with Astex's clinical pipeline products.
• ServiercoreGTM or Marketing PartnerCo-commercialization partnership for LONSURF (trifluridine/tipiracil). Servier holds rights for LONSURF in Europe and other territories outside US and Japan. Joint global development and commercialization with profit sharing in defined territories.
• Astex PharmaceuticalscoreOEM/ Whitelabel/ Licensing PartnerAstex Pharmaceuticals (wholly owned subsidiary of Otsuka Pharmaceutical) developed INQOVI (decitabine/cedazuridine) and related compounds. Taiho Oncology assumed commercialization responsibility from Otsuka for these products in US and Canada in 2019. Astex continues to supply and co-develop oral hypomethylating agents.
• National Comprehensive Cancer Network (NCCN)minorStrategic or Co-development PartnerNCCN Oncology Research Program collaboration with Taiho Oncology to study decitabine/cedazuridine and trifluridine/tipiracil. $2 million grants awarded to investigators from NCCN Member Institutions for clinical and pre-clinical evaluation of Taiho compounds in various cancers.

Scale indicators5 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Incyte Corporation: Specialty oncology/hematology innovator with Jakafi (ruxolitinib) franchise and a deep pipeline in MDS, myelofibrosis, and graft-versus-host disease. Highly comparable as a focused mid-cap US oncology company serving similar community and academic oncology prescribers.
• Daiichi Sankyo: Japanese oncology pharma with leading ADC platform (DXd, partnered with AstraZeneca for Enhertu) and growing hematology pipeline. Directly comparable as a Japanese-headquartered innovator oncology company expanding into ADC modalities, just as Taiho is doing through the Araris acquisition.
• Exelixis: Specialty oncology biotech with cabozantinib franchise in RCC and other indications. Comparable as a focused mid-cap US oncology company with a small number of approved products driving revenue and a pipeline targeting niche genomic populations.
• Cullinan Therapeutics: Taiho's co-development/co-commercialization partner on zipalertinib for EGFR exon 20 NSCLC. Highly comparable as a clinical-stage oncology company operating in close partnership with Taiho across overlapping indications and customer bases.
• Jazz Pharmaceuticals: Specialty oncology/hematology pharma with approved MDS/AML therapies including Vyxeos (CPX-351) and recent additions. Comparable product-focused franchise in hematologic malignancies that competes with INQOVI in similar indications.
• Servier: French-headquartered specialty oncology pharma and existing Taiho co-commercialization partner for LONSURF in ex-US territories. Directly comparable in oncology product portfolio depth and commercial model across hematologic and solid tumor oncology.

Broad incumbents

• Ipsen: European specialty oncology pharma with a similar mid-size product-focused franchise in targeted oncology including FGFR and other rare-cancer indications. Comparable as a specialty oncology company with a comparable revenue profile and geographic spread.
• Pfizer (with Seagen): Diversified large-cap oncology pharma that acquired Seagen for ADC leadership. Overlaps with Taiho across the oncology spectrum and is the dominant ADC competitor that the Araris-acquired platform will need to differentiate against.
• Bristol-Myers Squibb: Large diversified oncology pharma with deep hematology franchise (including decitabine competing with INQOVI) and ADC capabilities post-Celgene acquisition. Overlaps with Taiho in hematologic malignancies and solid tumors, making it a broad incumbent benchmark.
• Astellas Pharma: Japanese-headquartered specialty oncology pharma with Xtandi (enzalutamide) franchise and active ADC development. Comparable as a Japan-rooted multinational oncology company with strong US commercial presence and similar therapeutic breadth.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/TaihoOncology
• LinkedInlinkedin.com/company/taiho-oncology-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Taiho Oncology